Vanda Pharmaceuticals Sponsors IndyCar Entry for Washington D.C. Grand Prix

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is scheduled to compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. this weekend.

The event marks the first-ever Grand Prix held in the city, providing a prominent platform for Vanda's NEREUS™ product, developed for the treatment of rare diseases. This sponsorship is part of Vanda's initiative to raise awareness for the NEREUS™ brand and its potential benefits to patients.

Rahal Letterman Lanigan Racing is a recognized team in the IndyCar series, and Mick Schumacher is a well-known racing driver. The partnership aims to leverage the visibility of the racing event to reach a broad audience, including motorsport fans and the general public.

The race is expected to draw significant spectator and media attention. Vanda Pharmaceuticals anticipates the sponsorship will enhance brand recognition for NEREUS™ as it moves toward market introduction.